Fabio Bagante1,2, Faiz Gani3, Eliza W Beal1, Katiuscha Merath1, Qinyu Chen1, Mary Dillhoff1, Jordan Cloyd1, Timothy M Pawlik4. 1. Department of Surgery, The Urban Meyer III and Shelley Meyer Chair in Cancer Research, The Ohio State University Wexner Medical Center, 395 W. 12th Ave., Suite 670, Columbus, OH, 43210, USA. 2. Department of Surgery, University of Verona, Verona, Italy. 3. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Surgery, The Urban Meyer III and Shelley Meyer Chair in Cancer Research, The Ohio State University Wexner Medical Center, 395 W. 12th Ave., Suite 670, Columbus, OH, 43210, USA. tim.pawlik@osumc.edu.
Abstract
BACKGROUND: The National Comprehensive Cancer Network (NCCN) guidelines recommend chemotherapy for patients with inoperable biliary tract cancers (BTC), as well as patients following resection of BTC with lymph node metastasis (N1)/positive margins (R1). We sought to define overall adherence, as well as long-term outcomes, with the NCCN guidelines for BTC using the National Cancer Database (NCDB). METHODS: A total of 176,536 patients diagnosed with BTC at a hospital participating in the NCDB between 2004 and 2015 were identified. RESULTS: Among all patients, 63% of patients received medical therapy (chemotherapy or best supportive care), 11% underwent surgical palliation, and 26% underwent curative-intent surgery. According to the NCCN guidelines, 86% (n = 152,245) of patients were eligible for chemotherapy, yet, only 42.2% (n = 64,615) received chemotherapy. Factors associated with a lower adherence with NCCN guidelines included patient age (> 65 years: OR = 1.02), ethnicity (Black: OR = 1.14, Hispanic: OR = 1.21, Asian: OR = 1.24), and insurance status (non-private: OR = 1.45, all p < 0.001). A smaller subset of patients was either recommended chemotherapy but refused (n = 9269, 10.6%) or had medical factors that contraindicated chemotherapy (n = 8275, 9.4%). On multivariable analysis, adjusting for clinical and tumor-specific factors, adherence with NCCN guidelines was associated with a survival benefit for patients receiving medical therapies (HR = 0.74) or undergoing curative-intent surgery (HR = 0.73, both p < 0.001). CONCLUSION: Less than half of patients with BTC received systemic chemotherapy in adherence with NCCN guidelines. While a subset of patients had contraindications or refused chemotherapy, other factors such as insurance status and ethnicity were associated with adherence. Adherence with chemotherapy guidelines may influence long-term outcomes.
BACKGROUND: The National Comprehensive Cancer Network (NCCN) guidelines recommend chemotherapy for patients with inoperable biliary tract cancers (BTC), as well as patients following resection of BTC with lymph node metastasis (N1)/positive margins (R1). We sought to define overall adherence, as well as long-term outcomes, with the NCCN guidelines for BTC using the National Cancer Database (NCDB). METHODS: A total of 176,536 patients diagnosed with BTC at a hospital participating in the NCDB between 2004 and 2015 were identified. RESULTS: Among all patients, 63% of patients received medical therapy (chemotherapy or best supportive care), 11% underwent surgical palliation, and 26% underwent curative-intent surgery. According to the NCCN guidelines, 86% (n = 152,245) of patients were eligible for chemotherapy, yet, only 42.2% (n = 64,615) received chemotherapy. Factors associated with a lower adherence with NCCN guidelines included patient age (> 65 years: OR = 1.02), ethnicity (Black: OR = 1.14, Hispanic: OR = 1.21, Asian: OR = 1.24), and insurance status (non-private: OR = 1.45, all p < 0.001). A smaller subset of patients was either recommended chemotherapy but refused (n = 9269, 10.6%) or had medical factors that contraindicated chemotherapy (n = 8275, 9.4%). On multivariable analysis, adjusting for clinical and tumor-specific factors, adherence with NCCN guidelines was associated with a survival benefit for patients receiving medical therapies (HR = 0.74) or undergoing curative-intent surgery (HR = 0.73, both p < 0.001). CONCLUSION: Less than half of patients with BTC received systemic chemotherapy in adherence with NCCN guidelines. While a subset of patients had contraindications or refused chemotherapy, other factors such as insurance status and ethnicity were associated with adherence. Adherence with chemotherapy guidelines may influence long-term outcomes.
Entities:
Keywords:
Biliary tract cancers; National Cancer Database; National Comprehensive Cancer Network guidelines
Authors: Hanna K Sanoff; William R Carpenter; Til Stürmer; Richard M Goldberg; Christopher F Martin; Jason P Fine; Nadine Jackson McCleary; Jeffrey A Meyerhardt; Joyce Niland; Katherine L Kahn; Maria J Schymura; Deborah Schrag Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Jason A Zell; Jessica M Rhee; Argyrios Ziogas; Steven M Lipkin; Hoda Anton-Culver Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-03 Impact factor: 4.254
Authors: D J Sargent; R M Goldberg; S D Jacobson; J S Macdonald; R Labianca; D G Haller; L E Shepherd; J F Seitz; G Francini Journal: N Engl J Med Date: 2001-10-11 Impact factor: 91.245
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Hari Nathan; Timothy M Pawlik; Christopher L Wolfgang; Michael A Choti; John L Cameron; Richard D Schulick Journal: J Gastrointest Surg Date: 2007-09-05 Impact factor: 3.452
Authors: T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura Journal: Br J Cancer Date: 2010-07-13 Impact factor: 7.640
Authors: Eliza W Beal; Rittal Mehta; J Madison Hyer; Anghela Paredes; Katiuscha Merath; Mary E Dillhoff; Jordan Cloyd; Aslam Ejaz; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2019-02-27 Impact factor: 3.452
Authors: Sarah R Kaslow; Zhongyang Ma; Leena Hani; Katherine Prendergast; Gerardo Vitiello; Ann Y Lee; Russell S Berman; Judith D Goldberg; Camilo Correa-Gallego Journal: J Surg Oncol Date: 2022-04-26 Impact factor: 2.885
Authors: Patrick J Sweigert; Emanuel Eguia; Haroon Janjua; Sean P Nassoiy; Lawrence M Knab; Gerard Abood; Paul C Kuo; Marshall S Baker Journal: Surg Open Sci Date: 2020-05-16